中枢性眩晕量表临床应用的队列研究
A Cohort Study on the Clinical Application of the Central Vertigo Scale

目的：探讨中枢性眩晕量表在内科中枢性眩晕患者中的临床应用效果。方法：回顾性选取在齐齐哈尔医学院附属第二医院卒中中心及眩晕门诊诊治的200例中枢性眩晕患者为研究对象，选取年限为2018年1月至2023年6月。采用简单化随机法将200例患者分为对照组(100例)和观察组(100例)。对照组患者不实施中枢性眩晕量表干预，观察组患者采用中枢性眩晕量表进行干预。观察并比较两组患者的神经功能损伤(NIHSS)评分、日常生活活动能力(ADL)评分、生活质量(SF-36)评分及不良事件发生率。结果：与干预前比较，干预后两组患者的NIHSS评分、ADL评分和SF-36评分均有所改善(P < 0.05)；与对照组比较，观察组患者的NIHSS评分明显更低(P < 0.05)，ALD和SF-36评分均明显更高(P < 0.05)，且不良事件发生率明显更低(P < 0.05)。结论：中枢性眩晕量表在内科中枢性眩晕患者中的干预效果显著，能有效改善患者的临床症状，缓解患者神经功能损伤程度，提高患者的日常生活活动能力和生活质量，能显著降低不良事件的发生，值得临床推广。
Objective: To investigate the clinical application effects of the Central Vertigo Scale in patients with medical central vertigo. Methods: A retrospective cohort study was conducted involving 200 patients with central vertigo diagnosed and treated at the Stroke Center and Vertigo Clinic of the Second Affiliated Hospital of Qiqihar Medical University between January 2018 and June 2023. Using a simplified randomization method, the patients were divided into a control group (100 patients) and an observation group (100 patients). The control group did not receive any intervention using the Central Vertigo Scale, while the observation group was intervened with the scale. The National Institutes of Health Stroke Scale (NIHSS) score, Activities of Daily Living (ADL) score, Short Form-36 (SF-36) quality of life score, and incidence of adverse events were observed and compared between the two groups. Results: Compared with pre-intervention levels, the NIHSS score, ADL score, and SF-36 score of both groups showed significant improvements after the intervention (P < 0.05). Furthermore, when compared with the control group, the observation group exhibited a significantly lower NIHSS score (P < 0.05), significantly higher ADL and SF-36 scores (P < 0.05), and a significantly lower incidence of adverse events (P < 0.05). Conclusion: The Central Vertigo Scale demonstrates significant intervention effects in patients with medical central vertigo, effectively improving clinical symptoms, alleviating neurological impairment, enhancing ADL and quality of life, and reducing the occurrence of adverse events. Therefore, it is worthy of clinical promotion.